In memory: George O. Waring III, MD, FACS, FRCOphth
|
George O. Waring III, MD, FACS, FRCOphth, renowned ophthalmologist and expert in refractive surgery, has died. He was 73.
Dr. Waring received his medical degree from Baylor College of Medicine, Houston, in 1967. He began his academic career in 1974 as assistant professor of ophthalmology at the University of California, Davis. Joining Emory University in Atlanta in 1979, Dr. Waring was later principal investigator of the Emory-sponsored investigations of LASIK, receiving the first physician-sponsored investigational device exemption from the FDA.
He was adjunct professor emeritus of ophthalmology, Emory University School of Medicine, and in private practice.
In 2004, he received the Life Achievement Honor Award from the American Academy of Ophthalmology and the Castroviejo Medal from the Cornea Society, among many other awards.
|
iFS intracorneal pocket software granted U.S. approval
|
The Food and Drug Administration has approved the creation of intracorneal pockets with the iFS Femtosecond Laser System, according to Abbott Medical Optics (Abbott Park, Ill.). The software upgrade is designed to create customized corneal inlay pockets.
|
Dry eye drug gains European positive opinion
|
Ikervis (ciclosporin) has received a positive opinion from the European Medicines Agency for the "treatment of severe keratitis in adult patients with dry eye disease, which has not improved despite treatment with tear substitutes," developer Santen Pharmaceutical (Osaka, Japan) said in a press release.
|
Iluvien granted additional European approvals
|
Iluvien (fluocinolone) has received marketing approval in both Finland and Luxembourg for the treatment of diabetic macular edema, developer Alimera Sciences (Alpharetta, Ga.) said in a press release.
Iluvien is a sustained release 190 mcg intravitreal implant.
|
Eylea recommended for CRVO/BRVO
|
Eylea (aflibercept) has been recommended for approval by the European Committee for Medicinal Products for Human Use for the treatment of visual impairment resulting from macular edema secondary to central or branch retinal vein occlusion (CRVO/BRVO), Regeneron (Tarrytown, N.Y.) said in a news release. The European submission was based on positive results from the phase 3 VIBRANT study and the drug's previous approval for macular edema secondary to CRVO.
|
Nicox may submit allergic conjunctivitis drug in U.S.
|
Nicox (Sophia Antipolis, France) had a positive pre-New Drug Application meeting with U.S. regulators for AC-170, a "novel topical formulation of cetirizine," the company said. Cetirizine is a second-generation histamine H1-receptor antagonist that has been marketed for more than 25 years, but this marks the first time it is being developed in topical form.
|
Gene therapy for choroideremia enters phase 1/2
|
Patient enrollment has begun in a phase 1/2 study of SPK-CHM for the treatment of choroideremia (CHM), developer Spark Therapeutics (Philadelphia) said in a news release. CHM is characterized by deletions or mutations in the CHM gene, resulting in defective, or absent, Rab escort protein 1 (REP-1) that manifests in childhood as night blindness and reduced visual fields in male children. Spark currently plans to enroll up to 10 patients afflicted with the CHM genetic mutation. Spark is collaborating with the University of Pennsylvania on the project. There is currently no approved treatment for CHM.
|
New CPT code for corneal hysteresis
|
A new, permanent Category I code (92145-Corneal hysteresis determination, by air impulse stimulation, unilateral or bilateral, with interpretation and report) has been published specifically for corneal hysteresis measurement provided by the Reichert Ocular Response Analyzer, Reichert Technologies (Buffalo, N.Y.) announced. The new code took effect on January 1, 2015. Previously, the test was under a Category III code, typically non-reimbursable by Medicare or other payers.
|
Mile High Ophthalmics to launch Verus device for cataract surgery
|
Mile High Ophthalmics (Denver, Colo.) will launch its Verus capsulorhexis device next month, the company said. Developed in conjunction with Malik Kahook, MD, University of Colorado, the device was designed "to facilitate surgeons' ability to make a completely round, centered opening in the capsule surrounding the lens of the eye." The device adheres to the capsule and remains stable during surgery.
|
RESEARCH BRIEFS
- Blindness and low body mass index (BMI) were significantly associated with primary open-angle glaucoma (POAG), according to a population-based, cross-sectional, case-control study of 2,067 African Americans. Emily S. Charlson, MD, and colleagues in the Primary Open-Angle African American Glaucoma Genetics (POAAGG) study recruited African Americans aged 35 years or older from low income, high unemployment, and lower education neighborhoods surrounding the University of Pennsylvania. Subjects underwent detailed interviews and eye examinations, measurement of visual acuity and intraocular pressure, and a detailed anterior and posterior segment examination, including gonioscopy, dilated fundus and optic disc examination, visual fields, stereo disc photography, optical coherence tomography, and measurement of central corneal thickness. There were 807 controls and 1,260 POAG cases; cases were more likely to have a lower BMI (P<0.01) and report a history of blindness (VA of ≤20/200; P<0.001). Controls were more likely to have diabetes (P=0.02) and be female (P<0.001). The study is published in Ophthalmology.
- Dry eye disease (DED) was strongly linked to environmental and occupational factors and constituted a major proportion of hospital-based outpatients, according to a study. J. Li and colleagues conducted a cross-sectional study of clinically defined moderate-to-severe dry eye patients in a consecutive hospital-based population. Of 6,657 consecutive outpatients older than 20 years, symptomatic dry eye occurred in 635 subjects (9.54%). Of these, 532 (7.99%) were diagnosed as having DED. Women were significantly more likely than men to have DED (10.41% vs. 5.21%, respectively). Among younger men and women (56.2%), overexposure to visual display terminal constituted a major risk factor for DED. Occupational factors and exposure to adverse environmental conditions accounted for dry eye in more than half of the 532 patients. Contact lens use was implicated in young women, and a history of ocular surgeries was considered another factor in DED in older people. Hormonal changes resulted in dry eye in 163 of 371 female patients with dry eye (43.9%). Overall, the incidence of meibomian gland dysfunction increased gradually with age. The study is published in Eye & Contact Lens.
- The presence of a central hole in a posterior chamber phakic intraocular lens (pIOL) did not significantly affect the vault or refractive accuracy after implantation, according to a study. Kazutaka Kamiya, MD, and colleagues conducted a retrospective, comparative study in the eyes of patients who had central hole pIOL (Visian Implantable Collamer Lens, STAAR Surgical, Monrovia, Calif.) implantation in one eye and conventional pIOL implantation in the other eye. Quantitative assessment of the time course of the postoperative pIOL vault was conducted using a rotating Scheimpflug camera (Pentacam HR, Oculus, Arlington, Wash.). A total of 23 patients (46 eyes, mean age 31.3 years) were enrolled in the study. The amount of vault with the central hole pIOL was 603±276 μm, 552±261 μm, 539±258 μm, 520±240 μm, and 482±245 μm, at 1 week, 1 month, 3 months, 6 months, and 1 year postoperatively, respectively. Comparatively, during the same follow-up time points, the conventional pIOL vault was 585±252 μm, 550±269 μm, 514±253 μm, 485±233 μm, and 459±239 μm, respectively. There was no significant association between the pIOL vault and the refractive accuracy 1 year postoperatively. This study was published in the Journal of Cataract & Refractive Surgery.
NEW PRODUCT BRIEFS
- SynergEyes (Carlsbad, Calif.) launched the "Transform" campaign to highlight the benefits of hybrid contact lens technology. The new campaign is aimed at consumers and eyecare providers.
|
|
|
|
EyeWorld Weekly Update is edited by Stacy Majewicz and Michelle Dalton.
EyeWorld Weekly Update (ISSN 1089-0319), a digital publication of the American Society of Cataract and Refractive Surgery and the American Society of Ophthalmic Administrators, is published every Friday, distributed by email, and posted live on Friday.
Medical Editors: David F. Chang, MD, chief medical editor; Bonnie An Henderson, MD, cataract editor; Clara C. Chan, MD, cornea editor; Reay H. Brown, MD, glaucoma editor; Eric D. Donnenfeld, MD, refractive editor; and John A. Vukich, MD, international editor For sponsorship opportunities or membership information, contact: ASCRS*ASOA * 4000 Legato Rd. * Suite 700 * Fairfax, VA 22033 * Phone: 703-591-2220 * Fax: 703-591-0614 * Email: ASCRSOpinions expressed in EyeWorld Weekly Update do not necessarily reflect those of ASCRS*ASOA. Mention of products or services does not constitute an endorsement by ASCRS*ASOA.
|
|
|
|
|